MHPS’ T-Point 2 Enters Commercial Operation with the World’s Largest and Most Efficient 60 Hz Gas Turbine
1.7.2020 22:24:00 EEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems, Ltd. (MHPS) announced today that its T-Point 2 combined cycle power plant validation facility entered full commercial operation with an enhanced JAC gas turbine that sets the record for output and efficiency. The T-Point 2 plant was commissioned in March at Takasago Works in Hyogo Prefecture, Japan, to replace MHPS’ original T-Point plant and to continue MHPS’ approach — which is unlike any other manufacturer’s — to advance the limits of technology while minimizing risk to its customers. To do this, MHPS validates its new gas turbine technologies and digital solutions under long-term grid-connected operation for a minimum of 8,000 operating hours, which is equivalent to nearly one year of normal operation and is a key insurance industry criterion for fleet reliability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005896/en/
Mitsubishi Hitachi Power Systems’ T-Point 2 combined cycle power plant validation facility has entered full commercial operation with an enhanced JAC gas turbine that sets the record for output and efficiency. Shown: T-Point 2 at Takasago Works in Hyogo Prefecture, Japan. (Photo: Business Wire)
MHPS’ most advanced JAC gas turbine, designed for maximum efficiency and lower emissions, is now integrated with MHPS-TOMONI® digital solutions for verification and validation at T-Point 2. The gas turbine is entering commercial operation at record-setting combined cycle efficiency greater than 64% and a world’s first turbine inlet temperature of 1650°C. This gas turbine reduces carbon emissions by 65% versus coal-fired plants. In addition, it has the capability for conversion from natural gas to a blend of natural gas with 30% renewable hydrogen to reduce emissions further. Eventually it will be capable of running on 100% renewable hydrogen to completely eliminate carbon emissions.
The digital building blocks of the autonomous power plant being validated at T-Point 2 include an advanced Automatic Plant Startup package that is closely linked to the advanced analytics and diagnostics that continuously monitor the total plant. To validate complete remote operation, operations will be transferred from the local control room to the Takasago Remote Monitoring Center. Operations and maintenance building blocks under evaluation include an advanced array of acoustic, video, and thermographic data acquisition sensors monitored by advanced analytics that are being trained to identify pattern changes. T-Point 2 is also evaluating the first ever Netmation 4S Digital Control System to be used on an advanced class gas turbine combined cycle plant. Netmation 4S adds additional reliability, redundancy, and enhanced operator experience to the well-proven Netmation family of control systems.
“Unlike other manufacturers, MHPS demonstrates new gas turbine capabilities at our own combined cycle power plant before shipping to our customers. This enables us to provide unmatched performance, such as the 99.5% reliability of our J-Series gas turbines,” said Paul Browning, President and CEO of MHPS Americas and Chief Regional Officer for Europe, the Middle East, Africa and the Americas. “I congratulate our dedicated team of Engineers, Procurement, and Construction personnel for achieving commercial operation on schedule, on budget, and exceeding output and efficiency expectations. This project positions us years ahead of any manufacturer in putting the latest generation of 1650°C gas turbine technology into commercial operation. We are leading a Change in Power.”
About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS recently announced that its name will soon change to Mitsubishi Power. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com
Follow us at
https://twitter.com/MHPS_Global, or
https://www.linkedin.com/company/mitsubishi-hitachi-power-systems/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005896/en/
Contact information
Communications Contact:
Sharon Prater
US: +1 407-688-6200
Sharon.Prater@amer.mhps.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 15:00:00 EEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom